FULGENT GENETICS, INC. Restructuring Costs
FULGENT GENETICS, INC. (FLGT) reported Restructuring Costs of -$26.00 thousand for the 3-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2025-02-28
- FULGENT GENETICS, INC. restructuring costs for the quarter ending 2022-12-31 was -$26.00K.
- FULGENT GENETICS, INC. restructuring costs for the quarter ending 2022-09-30 was $105.00K.
- FULGENT GENETICS, INC. restructuring costs for the quarter ending 2022-06-30 was $2.90M.
- FULGENT GENETICS, INC. restructuring costs for fiscal 2022 was $2.98M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$26.00K 10-K · filed 2023-02-28 | $79.00K derived: sum of 2 quarters · filed 2023-11-03 | $2.98M derived: sum of 3 quarters · filed 2023-11-03 | $2.98M 10-K · filed 2025-02-28 |
| 2022-09-30 | $105.00K 10-Q · filed 2023-11-03 | $3.00M derived: sum of 2 quarters · filed 2023-11-03 | $3.00M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $2.90M 10-Q · filed 2023-08-04 | $2.90M 10-Q · filed 2023-08-04 | ||
| 2021-12-31 | $0.00 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |